Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance
Cancers · 25.11.2024 · 16 (23) · 3944
DOI: 10.3390/cancers16233944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.11.2024. Verfasst von Ali Gawi Ermi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Cancer Institute (NCI).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and the development of effective treatment strategies remains a significant challenge in the management of advanced HCC patients. The emergence of tyrosine kinase inhibitors (TKIs) has been a significant advancement in the treatment of HCC, as these targeted therapies have shown promise in prolonging the survival of patients with advanced disease. Although immunotherapy is currently considered as the first line of treatment for advanced HCC patients, many such patients do not meet the clinical criteria to be eligible for immunotherapy, and in many parts of the world there is still lack of accessibility to immunotherapy. As such, TKIs still serve as the first line of treatment and play a major role in the treatment repertoire for advanced HCC patients. However, the development of resistance to these agents is a major obstacle that must be overcome. In this review, we explore the underlying mechanisms of resistance to TKIs in HCC, the clinical implications of this resistance, and the potential strategies to overcome or prevent the emergence of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Human and Molecular Genetics, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
ORCID-Profile: Devanand Sarkar
Förderung
- NIH HHS
- NCI NIH HHS
- National Cancer Institute (NCI)
Zitieren
APA
Gawi Ermi, A., & Sarkar, D. (2024). Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance. Cancers, 16(23), 3944. https://doi.org/10.3390/cancers16233944
Vancouver
Gawi Ermi A, Sarkar D. Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance. Cancers. 2024;16(23):3944. doi:10.3390/cancers16233944
BibTeX
@article{GawiErmi2024,
author = {Gawi Ermi, Ali and Sarkar, Devanand},
title = {Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance},
journal = {Cancers},
year = {2024},
volume = {16},
number = {23},
pages = {3944},
doi = {10.3390/cancers16233944}
}
EUVIMED